Archived Monthly Oncology Tumor Boards: Management of Relapsed/Refractory Mantle Cell Lymphoma
Clinicians are challenged to remain up-to-date about the treatment advances that will enable them to make informed decisions to optimize the clinical outcome of patients with relapsed/refractory disease.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
How to Optimize Systemic Therapy Outside of the Cancer Center: Best Practices for Managing Anticancer Therapies
Educating clinicians about the various strategies that can be employed to improve the effective delivery of anticancer therapy will enable the incorporation of these strategies into routine clinical practice. 
Category
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
The Art of Creating and Sustaining Interprofessional Teams to Provide Comprehensive Care Throughout the Patient Journey
Clinicians need to be educated on the vast and varied impact cancer can have on individuals, the barriers to receipt of high-quality care, and the various professionals who can be part of their team to provide comprehensive care and improve patient outcomes. Information on approaches to build, maintain, and support such teams is also needed so that patients can benefit.
Category
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Management of Central Nervous System Metastases
As a result of advances in diagnosis and treatment, many patients improve with proper management and do not die of progression of these metastatic lesions. As CNS-active systemic agents are changing paradigms for the management of brain metastases, it is important to acknowledge that there is a paucity of prospective data to characterize optimal strategies regarding radiation and systemic therapy combinations or sequencing.
Category
  • Central Nervous System Cancers
  • Central Nervous System Cancers
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Team-Based Management of Immunotherapy-Related Toxicities
Education on this topic will enable clinicians to more rapidly identify when they may need to seek the expertise of disease specialists, and which specialists may be most relevant to their patients’ needs.
Category
  • Management of Immunotherapy-Related Toxicities
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Neoadjuvant and Adjuvant Therapy for Patients with Resectable Early-Stage and Locally Advanced Non-Small Cell Lung Cancer
Clinicians need to know the nuances of using neoadjuvant and adjuvant targeted therapy and immunotherapy to improve outcomes for their patients with resected early-stage and locally advanced NSCLC.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Recorded Presentation from the NCCN Pharmacy Updates: Changing Treatment Paradigms in Chronic Lymphocytic Leukemia
Since not all patients have access to a CLL specialist, the oncology pharmacist assumes an important role in understanding the best available clinical research, pairing that with the individual patient, and evaluating the outcomes to optimize patient care.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Management of Recurrent or Metastatic Cervical Cancer
The systemic therapy section of the NCCN Guidelines for Cervical Cancer has continuously added new therapy options over the past few years to reflect the new approvals. Knowledge in this topic will guide the practitioners in appropriately prioritizing these new treatment options to further improve patient outcomes.
Category
  • Cervical Cancer
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
New First-Line Systemic Treatment Options for Metastatic Esophageal Squamous Cell Carcinoma
Clinicians should be aware of the data supporting the use of immune checkpoint inhibitors, including nivolumab, in patients with various presentations of esophageal or esophagogastric junction cancers to identify the patients most likely to benefit from this treatment strategy.
Category
  • Gastric/Esophageal Cancer
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Radiation Therapy for Metastatic Brain Tumors
Whole-brain radiation therapy was historically the mainstay of treatment for brain metastases but has fallen out of favor in clinical practice over the last several decades. Strategies to promote cognitive preservation in patients with brain metastases is an area of active investigation. Clinicians need to remain up to date on these strategies.
Category
  • Central Nervous System Cancers
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Pages